1. Aleksandra Filippova. Non-alcoholic steatohepatitis in patients with obesity: interconnection between body mass, changes of lipid metabolism and concomitant pathology of biliary tract. doi:10.21303/2504-5679.2016.00115.

2. Moore, E. S., Daugherity, E. K., Karambizi, D. I., Cummings, B. P., Behling-Kelly, E., Schaefer, D. M. W., … Weiss, R. S. (2019). Sex-specific hepatic lipid and bile acid metabolism alterations in Fancd2-deficient mice following dietary challenge. Journal of Biological Chemistry, jbc.RA118.005729. doi:10.1074/jbc.ra118.005729.

3. Tazuma, S., Kanno, K., Sugiyama, A., & Kishikawa, N. (2013). Nutritional factors (nutritional aspects) in biliary disorders: Bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction. Journal of Gastroenterology and Hepatology, 28, 103–107. doi:10.1111/jgh.12241

4. Tazuma S. Gallstone disease: epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic). Best Pract. Res. Clin. Gastroenterol. 2006; 20: 1075–83.

5. Hyogo H, Tazuma S, Cohen DE. Cholesterol gallstones. Curr. Opin. Gastroenterol. 2002; 18: 366–71.

6. Ogiyama H, Kamada Y, Kiso S et al. Lack of adiponectin promotes formation of cholesterol gallstones in mice. Biochem. Biophys. Res. Commun. 2010; 399: 352–8.

7. Tazuma S. Homocysteine and gallstone diseases: is hyperhomocysteinemia a prerequisite for or secondary to gallstone formation? J. Gastroenterol. 2005; 40: 1085–7.

8. Tazuma S, Kajiyama G, Mizuno T et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J. Clin. Gastroenterol. 1998; 26: 287–91.

9. Tazuma S, Yamashita G, Ochi H et al. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. Clin. Ther. 1998; 20: 477–85.

10. Tazuma S, Takizawa I, Kunita T et al. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism 1995; 44: 1410–12

11. Tazuma S, Ohya T, Mizuno T et al. Effects of fluvastatin on human biliary lipids. Am. J. Cardiol. 1995; 76: 110A–3A.

12. Nishioka T, Hyogo H, Numata Y et al. A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. J. Atheroscler. Thromb. 2005; 12: 211–17.

13. Paigen K. A miracle enough: the power of mice. Nat. Med. 1995; 1: 215–20.

14. Lammert F, Carey MC, Paigen B. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. Gastroenterology 2001; 120: 221–38.

15. Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch. Surg. 2001; 386: 224–9.

16. Komichi D, Tazuma S, Nishioka T, Hyogo H, Une M, Chayama K. Unique inhibition of bile salt-induced apoptosis by lecithins and cytoprotective bile salts in immortalized mouse cholangiocytes. Dig. Dis. Sci. 2003; 48: 2315–22.

17. Komichi D, Tazuma S, Nishioka T, Hyogo H, Chayama K. Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radic. Biol. Med. 2005; 39: 1418–27.

18. Komichi D, Tazuma S, Nishioka T, Hyogo H, Chayama K. A nuclear receptor ligand downregulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists. Dig. Dis. Sci. 2005; 50: 514–24.

19. Tsuboi K, Tazuma S, Ochi H, Chayama K. Hydrophilic bile salts have a cytoprotective effect against cyclosporine A-induced cholestasis through enhanced canalicular membrane fluidity and transporter activity. Hepatol. Res. 2003; 25: 38–47.

20. Tsuboi K, Tazuma S, Nishioka T, Chayama K. Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage. J. Gastroenterol. 2004; 39: 955–60

21. Aihara N, Tazuma S, Kajiyama G. Hydrophilic bile salts and liposomes inhibit hydrophobic bile salt-induced release of glycoprotein by guinea-pig gall-bladder. J. Gastroenterol. Hepatol. 1995; 10: 42–6.

22. Nonaka M, Tazuma S, Hyogo H, Kanno K, Chayama K. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferatoractivated receptor gamma ligand. J. Gastroenterol. Hepatol. 2008; 23 (7 Pt 2): e198–206.

23. Tazuma S. Cyclosporin A and cholestasis: its mechanism(s) and clinical relevancy. Hepatol. Res. 2006; 34: 135–6.

24. Sagawa H, Tazuma S, Kajiyama G. Protection against hydrophobic bile salt-induced cell membrane damage by liposomes and hydrophilic bile salts. Am. J. Physiol. 1993; 264 (5 Pt 1): G835–9.

25. Tazuma S, Holzbach RT. Transport of conjugated bilirubin and other organic anions in bile: relation to biliary lipid structures. Proc. Natl Acad. Sci. U. S. A. 1987; 84: 2052–6.